Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
24 hedge funds and large institutions have $182M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 4 closing their positions.
105% more capital invested
Capital invested by funds: $89M → $182M (+$93.4M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
4% more funds holding
Funds holding: 23 → 24 (+1)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.89M |
| 2 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
+$1.68M |
| 3 |
AIP
Almanack Investment Partners
Wayne,
Pennsylvania
|
+$1.51M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$416K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$112K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$1.14M |
| 2 |
FO
FT Options
Chicago,
Illinois
|
-$615K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$338K |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$280K |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$155K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AFM
26
Anson Funds Management
Dallas,
Texas
| – | -$155K | -104 | Closed |
|
27
Renaissance Technologies
New York
| – | -$103K | -69 | Closed |
|
|
WT
28
Wellcome Trust
London,
United Kingdom
| – | -$81K | -54 | Closed |
|
29
UBS Group
Zurich,
Switzerland
| – | -$7K | -5 | Closed |
|
NBRV Hedge Fund Activity: Q1 2017 in Review
24 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q1 2017, worth a combined $182M — up 105% from $89M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NBRV positions and 4 closed out — a net gain of 1 holder — while 3 added to existing stakes and 6 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $1.89M. The largest seller was Tekla Capital Management, cutting an estimated $1.14M.
- 24 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q1 2017, up from 23 in Q4 2016.
- Funds reported $182M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q1 2017, up 105% quarter-over-quarter.
- 5 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q1 2017 and 4 closed out, a net change of +1 holder.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q1 2017 was Wellington Management Group, an estimated $1.89M added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q1 2017 was Tekla Capital Management, an estimated $1.14M sold.
Based on aggregated 13F filings for Q1 2017.